BridgeBio Oncology Therapeutics Inc.
$8.19
-0.97%BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.9).
Valuation inputs: P/E -1.9, earnings yield N/A, momentum -1.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -32.6%, ROIC -35.2%).
Profitability stack: net margin 0.0%, ROE -32.6%, ROIC -35.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.3%, momentum -1.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
BridgeBio Oncology Therapeutics Inc. Market vs Earnings Trajectory
Loading price and EPS data...
BridgeBio Oncology Therapeutics Inc. Fair Value Envelope
No Revenue Data
BBOT has not reported any revenue values in the available annual periods.
BridgeBio Oncology Therapeutics Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
BBOT has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
BBOT has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
BBOT has not reported any net profit margin values in the available annual periods.
BridgeBio Oncology Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
BridgeBio Oncology Therapeutics Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BridgeBio Oncology Therapeutics Inc. Street Expectations Map
Wall Street analysts project that BBOT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 22.00, with estimates ranging from a low of 18.00 to a high of 24.00.
The consensus 1-year price target stands at 22.00, with estimates ranging from a low of 18.00 to a high of 24.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
BridgeBio Oncology Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $40.50M and sold $420K worth of BBOT shares, resulting in $40.08M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.6M
20.08M
0
0.00
+20.1M
+$20.08M
9-12 Months
2.1M
20.42M
81.1K
419.94K
+20.0M
+$20.00M
Top Buyers
Wallace Eli M.
Director, Officer: Chief Executive Officer
$24.88M
Mehra Uneek
Officer: Chief Financial Officer
$6.08M
Beltran Pedro
Officer: Chief Scientific Officer
$3.43M
Ben Yong
Officer: Chief Med & Dev Officer
$3.43M
Bauer Jake
Director
$1.33M
Top Sellers
Tipirneni Praveen P.
Director
$420K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $40.08M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
BBOT has not reported any dividend yield values in the available annual periods.
bbot Dividend History
Learning Layer
Related Guides
Build conviction on BBOT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.